KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)
OBG PED-001
Phase 2 small_molecule completed
Quick answer
KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S) for Persistent Corneal Epithelial Defect is a Phase 2 program (small_molecule) at KIORA PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- KIORA PHARMACEUTICALS INC
- Indication
- Persistent Corneal Epithelial Defect
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed